Hemogenyx Pharmaceuticals (LON:HEMO) Trading Down 6.4% – Here’s Why

Shares of Hemogenyx Pharmaceuticals Plc (LON:HEMOGet Free Report) dropped 6.4% during mid-day trading on Wednesday . The company traded as low as GBX 0.95 ($0.01) and last traded at GBX 0.96 ($0.01). Approximately 6,211,438 shares were traded during mid-day trading, a decline of 38% from the average daily volume of 10,021,008 shares. The stock had previously closed at GBX 1.03 ($0.01).

Hemogenyx Pharmaceuticals Stock Up 9.8 %

The company has a 50 day moving average of GBX 1.34 and a 200-day moving average of GBX 1.36. The company has a debt-to-equity ratio of 92.09, a current ratio of 4.38 and a quick ratio of 6.72. The company has a market cap of £15.75 million, a P/E ratio of -114.00 and a beta of 3.14.

About Hemogenyx Pharmaceuticals

(Get Free Report)

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.

Read More

Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.